At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 48 enrolled
Drug / intervention
florbetapir (18F)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
In Brief
A Phase 3 clinical trial evaluating florbetapir (18F) for Alzheimer's Disease and Mild Cognitive Impairment. Completed, enrolled 48 participants across 2 sites.
Detailed Summary
Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Mild Cognitive Impairment
CountriesJapan
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartOct 2012
Primary CompletionFeb 2013
TodayJul 2026
First PostedAug 13, 2012
Enrollment StartOct 1, 2012
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.9 years ago
Interventions
florbetapir (18F)drug
IV injection, 370 MBq(10mCi), single dose